Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 1999, for Celsion Corporation (Note: The input metadata lists "Imunon, Inc.", but the filing text explicitly identifies the registrant as Celsion Corporation). The Company is a clinical-stage biotechnology firm focused on thermotherapy systems for cancer treatment. It has incurred substantial operating losses since inception and relies on equity financing to fund research, development, and clinical trials.
Key Financial Metrics
| Metric | Three Months Ended 6/30/1999 | Nine Months Ended 6/30/1999 | Balance Sheet (6/30/1999) |
|---|---|---|---|
| Total Revenue | $0 | $0 | N/A |
| Net Loss | $(427,571) | $(1,588,465) | N/A |
| Operating Expenses | $427,144 | $1,537,074 | N/A |
| Cash and Equivalents | N/A | N/A | $866,661 |
| Working Capital | N/A | N/A | $593,667 (Surplus) |
| Accumulated Deficit | N/A | N/A | $(21,052,477) |
| Outstanding Shares | 46.9M (Wtd Avg) | 43.8M (Wtd Avg) | 50.8M (Issued) |
Material Changes vs. Prior Period
- Revenue: The Company reported zero revenue for the three and nine months ended June 30, 1999, compared to $110,260 in the prior year period. The prior year revenue consisted of re-orders for older equipment which is no longer marketed.
- Operating Loss: The net loss decreased significantly to $(1,588,465) for the nine months ended June 30, 1999, compared to $(3,521,826) in the prior year. This improvement was driven by reduced operating expenses.
- Expense Reductions: Selling, general, and administrative (SG&A) expenses dropped from $2,239,292 to $853,470 (nine months). This decrease was primarily due to the absence of non-cash stock-based compensation ($700,640), consulting fees ($195,297), legal fees ($175,000), and inventory write-offs ($112,000) recorded in the prior year.
- Liquidity: Cash balances increased from $54,920 at September 30, 1998, to $866,661 at June 30, 1999. Working capital improved from a deficit of $(1,851,067) to a surplus of $593,667.
Guidance, Outlook, and Risks
- Capital Requirements: Management revised its 1999 spending plan downward to approximately $6 million (from a previous $10 million estimate). As of June 30, 1999, the Company had raised $2.3 million, leaving approximately $3.7 million to be raised for the remainder of the year.
- Financing Activities: The Company closed a private placement on June 15, 1999, raising $1,305,000. Additionally, $1,040,932 of debt and accrued compensation was converted into common stock.
- Going Concern: The filing includes a going concern uncertainty. Continued operations depend on the ability to secure additional funding to complete clinical trials and obtain regulatory approvals. Without funding, the Company may breach licensing agreements and lose rights to its technology.
- Warrant Redemption: On July 21, 1999, the Company elected to redeem Series 700 Warrants. It expects holders to exercise these warrants at $0.50 per share rather than accept the redemption price, potentially generating additional capital.
- Year 2000 Compliance: The Company believes its systems are Y2K compliant with estimated upgrade costs below $8,000, posing no material financial risk.
Investor Verification Checklist
- Verify the Company's ability to raise the remaining $3.7 million required for 1999 operations.
- Confirm the status of the Series 700 Warrant redemption and expected proceeds from exercises.
- Monitor the timeline for the commencement of Phase II BPH and Phase I breast cancer clinical trials.
- Assess the risk of breaching licensing agreements with research institutions due to funding shortfalls.
- Review the dilution impact of the recent stock issuances (2.6 million shares for cash and 2.1 million shares for debt conversion).